Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 187

1.

Application of the polyvalent approach to HIV-1 vaccine development.

Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou TH, Lu S.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):143-56. Review.

PMID:
15975020
[PubMed - indexed for MEDLINE]
2.

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT.

Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819. Review.

PMID:
18197170
[PubMed - indexed for MEDLINE]
3.

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S.

Virology. 2006 Jun 20;350(1):34-47. Epub 2006 Apr 17.

PMID:
16616287
[PubMed - indexed for MEDLINE]
Free Article
4.

HIV vaccines: brief review and discussion of future directions.

Slobod KS, Bonsignori M, Brown SA, Zhan X, Stambas J, Hurwitz JL.

Expert Rev Vaccines. 2005 Jun;4(3):305-13. Review.

PMID:
16026246
[PubMed - indexed for MEDLINE]
5.

Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

Lockey TD, Slobod KS, Caver TE, D'Costa S, Owens RJ, McClure HM, Compans RW, Hurwitz JL.

Immunol Res. 2000;21(1):7-21.

PMID:
10803879
[PubMed - indexed for MEDLINE]
6.

Polyvalent AIDS vaccines.

Lu S, Grimes Serrano JM, Wang S.

Curr HIV Res. 2010 Dec;8(8):622-9. Review.

PMID:
21054250
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.

McBurney SP, Ross TM.

Curr Pharm Des. 2007;13(19):1957-64. Review.

PMID:
17627529
[PubMed - indexed for MEDLINE]
8.

HIV vaccine rationale, design and testing.

Slobod KS, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, Zirkel A, Jones BG, Sealy RE, Stambas J, Brown B, Lockey TD, Freiden PJ, Doherty PC, Blanchard JL, Martin LN, Hurwitz JL.

Curr HIV Res. 2005 Apr;3(2):107-12. Review.

PMID:
15853717
[PubMed - indexed for MEDLINE]
9.

HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS.

Front Biosci. 2008 Jan 1;13:609-20. Review.

PMID:
17981574
[PubMed - indexed for MEDLINE]
10.

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Stamatatos L, Morris L, Burton DR, Mascola JR.

Nat Med. 2009 Aug;15(8):866-70. doi: 10.1038/nm.1949. Review.

PMID:
19525964
[PubMed - indexed for MEDLINE]
11.

Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.

Pinter A.

Curr HIV Res. 2007 Nov;5(6):542-53. Review.

PMID:
18045110
[PubMed - indexed for MEDLINE]
12.

A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.

Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, Brahic M, Tangy F.

Vaccine. 2005 Aug 22;23(36):4463-72.

PMID:
15993518
[PubMed - indexed for MEDLINE]
13.

Rational modifications of HIV-1 envelope glycoproteins for immunogen design.

Phogat S, Wyatt R.

Curr Pharm Des. 2007;13(2):213-27. Review.

PMID:
17269929
[PubMed - indexed for MEDLINE]
14.

Bioorganic approaches towards HIV vaccine design.

Wang LX.

Curr Pharm Des. 2003;9(22):1771-87. Review.

PMID:
12871196
[PubMed - indexed for MEDLINE]
15.

Diversity considerations in HIV-1 vaccine selection.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B.

Science. 2002 Jun 28;296(5577):2354-60. Review.

PMID:
12089434
[PubMed - indexed for MEDLINE]
16.

Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.

Maksyutov AZ, Bachinskii AG, Bazhan SI, Ryzhikov EA, Maksyutov ZA.

J Clin Virol. 2004 Dec;31 Suppl 1:S26-38.

PMID:
15567091
[PubMed - indexed for MEDLINE]
17.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

PMID:
16227256
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.

Evans TG, Frey S, Israel H, Chiu J, El-Habib R, Gilbert P, Gaitan A, Montefiori DC; HIV Vaccine Trials Network (HVTN 803).

Vaccine. 2004 Jun 30;22(20):2626-30.

PMID:
15193388
[PubMed - indexed for MEDLINE]
19.

Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.

Lin G, Nara PL.

Curr HIV Res. 2007 Nov;5(6):514-41. Review.

PMID:
18045109
[PubMed - indexed for MEDLINE]
20.

Subunit protein vaccines: theoretical and practical considerations for HIV-1.

Cho MW.

Curr Mol Med. 2003 May;3(3):243-63. Review.

PMID:
12699361
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk